Trials / Unknown
UnknownNCT04336488
Matrix Metalloproteinases Neutralizing Agents in Oral Lichen Planus
Effectiveness of Matrix Metalloproteinase Neutralizing Agent in Treatment of Oral Lichen Planus: A Pilot Study
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Jaylane kadry Ghonima · Academic / Other
- Sex
- All
- Age
- 25 Years
- Healthy volunteers
- Not accepted
Summary
The current study will be conducted to evaluate the effectiveness of matrix metalloproteinases inhibitors on erosive oral lichen planus.
Detailed description
Matrix metalloproteinases inhibitor (Orochem) will be given to patients with Oral erosive lichen planus three times daily for 3 weeks. Then the subjective discomfort and pain severity as well as the objective disease severity scores will be collected.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Matrix Metalloproteinase Inhibitors (Orochem) | topical application of MMP inhibitors for 3 weeks to evaluate its effectiveness in treating oral lichen planus |
| DRUG | Kenacort A, | topical application of both drugs 3 times daily for 3 weeks as an active control |
Timeline
- Start date
- 2020-01-01
- Primary completion
- 2020-06-01
- Completion
- 2020-07-01
- First posted
- 2020-04-07
- Last updated
- 2020-06-19
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT04336488. Inclusion in this directory is not an endorsement.